RPS6-KD alone reduced the proliferation of two human melanoma cells A375-DR and A375-TR, which are resistant to the BRAFV600E-selective inhibitor dabrafenib and the MEK1/2 inhibitor trametinib [39]. This evidence concerns the gene MAP2K1 and melanoma.